Chemotherapy for Leukemia

Novel Drugs and Treatment

  • Takanori¬†Ueda

Table of contents

  1. Front Matter
    Pages i-viii
  2. Takanori Ueda
    Pages 1-7
  3. Bcr-Abl Tyrosine Kinase Inhibitors (TKIs)

    1. Front Matter
      Pages 9-9
    2. Fujiko Tsukahara, Yoshiro Maru
      Pages 11-31
  4. New Antibodies for Leukemia

  5. Signaling Inhibitors

    1. Front Matter
      Pages 165-165
    2. Hitoshi Kiyoi
      Pages 167-179
  6. Differentiating Agents

  7. New Chemotherapeutic Agents Including Antimetabolite

    1. Front Matter
      Pages 239-239
    2. Takahiro Yamauchi, Takanori Ueda
      Pages 241-250
    3. Takahiro Yamauchi, Takanori Ueda
      Pages 251-260
    4. William B. Parker, Varsha Gandhi
      Pages 261-286
    5. James McCloskey, Jamie Koprivnikar, Stefan Faderl, Dirk Reinhardt, Nobuko Hijiya
      Pages 287-309
    6. Dzjemma Sarkisjan, Renske D. M. Steenbergen, Jacqueline Cloos, Godefridus J. Peters
      Pages 311-326
  8. Therapy Targeting Leukemic Stem Cells

    1. Front Matter
      Pages 341-341
    2. Taira Maekawa
      Pages 343-361

About this book


This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells.

This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.


Acute promyelocytic leukemia Chronic myeloid leukemia Molecular targeted agent antimetabolite analogues chemokine receptor 4 epigenetic regulator leukemic stem cells signaling inhibitors

Editors and affiliations

  • Takanori¬†Ueda
    • 1
  1. 1.University of FukuiFukuiJapan

Bibliographic information

  • DOI
  • Copyright Information Springer Nature Singapore Pte Ltd. 2017
  • Publisher Name Springer, Singapore
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-981-10-3330-8
  • Online ISBN 978-981-10-3332-2
  • Buy this book on publisher's site